Skip to main content

Table 1 Association of MKP-4 expression, ERK1/2 expression and p-ERK1/2 expression with clinicopathological parameters in 160 hepatocellular carcinoma specimens

From: MKP-4 suppresses hepatocarcinogenesis by targeting ERK1/2 pathway

Parameters Total MKP-4 expression P ERK1/2 expression P p-ERK1/2 expression P
Low High Low High Low High
Age
 ≤ 45 82 66 16 0.051 24 58 0.060 36 46 0.902
 > 45 78 51 27   34 44   35 43  
Gender
 Female 35 25 10 0.798 13 22 0.901 13 22 0.330
 Male 125 92 33   45 80   58 67  
Tumor differentiation
 I–II 78 46 32 < 0.001* 37 41 0.004* 41 37 0.042*
 III–IV 82 71 11   21 61   30 52  
Tumor size
 ≤ 5 92 67 25 0.921 30 62 0.265 42 50 0.705
 > 5 68 50 18   28 40   29 39  
HBsAg
 Negative 31 25 6 0.293 11 20 0.921 14 17 0.922
 Positive 129 92 37   47 82   57 72  
Liver cirrhosis
 Negative 49 39 10 0.220 14 35 0.179 23 26 0.665
 Positive 111 78 33   44 47   48 63  
Tumor encapsulation
 None 60 44 16 0.963 21 39 0.799 31 29 0.150
 Complete 100 73 27   37 63   40 60  
Child–Pugh score
 A 77 58 19 0.545 31 44 0.310 36 41 0.560
 B 83 59 24   27 56   35 48  
Microvascular invasion
 Negative 65 40 25 0.006* 30 35 0.031* 28 37 0.785
 Positive 95 77 18   28 67   43 52  
AFP (ng/ml)
 ≤ 50 122 93 29 0.112 40 82 0.103 52 70 0.424
 > 50 38 24 14   18 20   19 19  
TNM stage
 I–II 84 54 30 0.008* 38 46 0.013* 45 39 0.014*
 III–IV 76 63 13   20 56   26 50  
Tumor number
 Single 78 60 18 0.504 27 51 0.675 38 46 0.902
 Multiple 82 57 25   31 51   20 56  
  1. Statistical analyses were performed by the Pearson χ2 test
  2. P < 0.05 was considered significant